Progenics Pharmaceuticals, Inc. - Product Pipeline Review - Q1 2011

Date: May 1, 2011
Pages: 62
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P54F7878C64EN
Leaflet:

Download PDF Leaflet

Progenics Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Progenics Pharmaceuticals, Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Progenics Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Progenics Pharmaceuticals, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Progenics Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Progenics Pharmaceuticals, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate Progenics Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Progenics Pharmaceuticals, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Progenics Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Progenics Pharmaceuticals, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Progenics Pharmaceuticals, Inc. and identify potential opportunities in those areas.
Table of Content
Table of Content
List of Tables
List of Figures
Progenics Pharmaceuticals, Inc. Snapshot
Progenics Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Progenics Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Progenics Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Progenics Pharmaceuticals, Inc. – Pipeline Products Glance
Progenics Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Progenics Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Progenics Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Progenics Pharmaceuticals, Inc. – Drug Profiles
Methylnaltrexone
Product Description
Mechanism of Action
R&D Progress
Oral Methylnaltrexone
Product Description
Mechanism of Action
R&D Progress
Subcutaneous Methylnaltrexone
Product Description
Mechanism of Action
R&D Progress
Oral Methylnaltrexone
Product Description
Mechanism of Action
R&D Progress
PRO 140
Product Description
Mechanism of Action
R&D Progress
PRO 542
Product Description
Mechanism of Action
R&D Progress
PSMA ADC
Product Description
Mechanism of Action
R&D Progress
PSMA VRP vaccine
Product Description
Mechanism of Action
R&D Progress
Clostridium Difficile Antibodies
Product Description
Mechanism of Action
R&D Progress
HCV entry inhibitor
Product Description
Mechanism of Action
R&D Progress
Multiplex PI3-Kinase Inhibitors
Product Description
Mechanism of Action
R&D Progress
PRO 206
Product Description
Mechanism of Action
R&D Progress
PSMA VRP vaccine
Product Description
Mechanism of Action
R&D Progress
Progenics Pharmaceuticals, Inc. – Pipeline Analysis
Progenics Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Progenics Pharmaceuticals, Inc. - Pipeline Products By Target
Progenics Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Progenics Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Progenics Pharmaceuticals, Inc. – Recent Pipeline Updates
Progenics Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
PRO 206
Progenics Pharmaceuticals, Inc. – Company Statement
Progenics Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Progenics Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2011
Progenics Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2011
Progenics Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011
Progenics Pharmaceuticals, Inc. Detailed Deal Summary
Asset Purchase
Progenics Pharmaceuticals Acquires Portion Of Royalty For methylnaltrexone
Acquisition
Progenics Pharmaceuticals Acquires PSMA Development Company From Cytogen
Equity Offering
Progenics Pharmaceuticals Completes Public Offering Of $60 Million
Progenics Pharmaceuticals Completes Public Offering Of $60 Million
Progenics Pharmaceuticals Completes Public Offering Of $29 Million
Progenics Pharmaceuticals Completes Public Offering Of $31 Million
Progenics Pharmaceuticals Enters Into Agreement With Seattle Genetics
Wyeth Enters Into Co-Development Agreement With Progenics Pharmaceuticals
Licensing Agreements
Ono Pharmaceutical Enters Into Licensing Agreement With Progenics Pharmaceuticals
Progenics Pharmaceuticals And Wyeth Pharmaceuticals Terminates Licensing Agreement
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Progenics Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2011
Progenics Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2011
Progenics Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2011
Progenics Pharmaceuticals, Inc. – Phase III, 2011
Progenics Pharmaceuticals, Inc. - Phase II, 2011
Progenics Pharmaceuticals, Inc. - Phase I, 2011
Progenics Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2011
Progenics Pharmaceuticals, Inc. - Pipeline By Target, 2011
Progenics Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2011
Progenics Pharmaceuticals, Inc. – Pipeline By Molecule Type, 2011
Progenics Pharmaceuticals, Inc. – Recent Pipeline Updates, 2011
Progenics Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2010
Progenics Pharmaceuticals, Inc., Subsidiaries
Progenics Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011
Progenics Pharmaceuticals, Inc., Deals Summary by Region, 2004 to YTD 2011
Progenics Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011

LIST OF FIGURES

Progenics Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2011
Progenics Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2011
Progenics Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2011
Progenics Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2011
Progenics Pharmaceuticals, Inc. - Pipeline By Target, 2011
Progenics Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2011
Progenics Pharmaceuticals, Inc. – Pipeline By Molecule Type, 2011

Ask Your Question

Progenics Pharmaceuticals, Inc. - Product Pipeline Review - Q1 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: